Adriamycin
(doxorubicin hydrochloride)Phase 3Small molecule
PfizerDoxorubicin is a chemotherapy drug used to treat various cancers including breast cancer, lymphomas, and leukemias by killing rapidly dividing cancer cells throughout the body.[1] Adriamycin is currently being investigated across 55 indications[3], with its most advanced program in Phase 3.[1]
Adriamycin is one of 699 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.
55
Indications
555
Total Trials
16
Active Trials
698
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 55 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 2Active, not recruiting
Rhabdomyosarcoma
NCT00077285
Phase 3Active, not recruiting
Acute Lymphoblastic Leukemia
NCT02883049
Phase 2Recruiting
Acute Lymphoblastic Leukemia
NCT02877303
Phase 3Active, not recruiting
Osteosarcoma
NCT00470223
Phase 2/3Active, not recruiting
Soft Tissue Sarcoma
NCT02180867
Phase 2Active, not recruiting
Lymphoma
NCT03749018
Clinical
Trials by Indication[1]
Lymphoma35 trials
Show 32 more trials
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00379041·1,158 enrolled
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT00060385·3 enrolled
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Active, not recruiting·—·Phase 2·NCT03749018·30 enrolled
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Active, not recruiting·—·Phase 1·NCT02337985·10 enrolled
Breast Cancer29 trials
Show 26 more trials
Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00093834·60 enrolled
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
Completed·—·Phase 1·NCT00005822·21 enrolled
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Completed·—·Phase 2·NCT00003953·39 enrolled
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
Completed·—·Phase 2·NCT00003042·41 enrolled
Acute Lymphoblastic Leukemia23 trials
Show 20 more trials
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
Neuroblastoma14 trials
Show 11 more trials
Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma
Completed·—·Phase 2·NCT00002803·44 enrolled
Soft Tissue Sarcoma12 trials
Show 9 more trials
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
Unknown status·EEuropean Paediatric Soft Tissue Sarcoma Study Group·Phase 3·NCT00334854·250 enrolled
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002641·350 enrolled
43 more indications
Diffuse Large B-Cell Lymphoma8 trials
Show 5 more trials
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Completed·—·Phase 1/2·NCT02073097·48 enrolled
Leukemia5 trials
Hodgkin's Disease5 trials
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000626·27 enrolled
Bladder Cancer4 trials
Liver Cancer4 trials
Show 1 more trial
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
Completed·—·Phase 1·NCT01042041·18 enrolled
Bone Marrow Transplantation4 trials
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1/2·NCT00003086·12 enrolled
Multiple Myeloma4 trials
Small Cell Lung Cancer4 trials
Endometrial Cancer3 trials
Osteosarcoma3 trials
Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002539·214 enrolled
Rhabdomyosarcoma3 trials
Anaplastic Large Cell Lymphoma2 trials
Chemotherapy2 trials
Kaposi's sarcoma2 trials
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000987·36 enrolled
A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000996·48 enrolled
Prostate Cancer2 trials
Radiation Therapy2 trials
Ewing's Sarcoma2 trials
Metastatic Prostate Cancer2 trials
Urothelial Cancer2 trials
Richter Transformation1 trial
Colorectal Cancer1 trial
Nausea and vomiting1 trial
Patients With Advanced Solid Tumors1 trial
Adult T-Cell Leukemia/lymphoma1 trial
Germ Cell Tumor1 trial
Induction Therapy1 trial
Advanced Cancer1 trial
Immunosuppression1 trial
Locally Advanced1 trial
Stem Cell Transplantation1 trial
B-cell acute lymphoblastic leukemia1 trial
Locally Advanced Solid Tumor1 trial
Adenoid Cystic Carcinoma1 trial
Lymphoblastic Lymphoma1 trial
HIV infection1 trial
Peritoneal Cancer1 trial
Transitional Cell Carcinoma1 trial
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00028756·285 enrolled
Newly Diagnosed1 trial
Refractory Solid Tumors1 trial
Head and Neck Cancer1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
DOXORUBICIN HYDROCHLORIDE
NDA NDA050467
Dec 23, 1987
DOXORUBICIN HYDROCHLORIDE
NDA NDA050629
Nov 17, 1995
DOXIL (LIPOSOMAL)
NDA NDA050718
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for doxorubicin hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]